Amgen Reports post-marketing Data for Pertuzumab in Hypertension

Amgen today announced post-marketing results for pertuzumab in patients with hypertension. The study demonstrated that pertuzumab reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of hypertension and support the continued development of pertuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.